Synonyms: OPC-167832
Compound class:
Synthetic organic
Comment: Quabodepistat is a 3,4-dihydrocarbostyril derivative. It is an inhibitor of decaprenylphosphoryl-beta-D-ribose oxidase (DprE1), an essential mycobacterial cell wall biosynthesis enzyme, and has potent antimycobacterial activity [3]. Quabodepistat is under clinical development by Otsuka Pharmaceutical (Tokyo, Japan) as a treatment for tuberculosis (TB).
|
|
References |
1. Dawson R, Diacon AH, Narunsky K, De Jager VR, Stinson KW, Zhang X, Liu Y, Hafkin J. (2023)
Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832. Antimicrob Agents Chemother, 67 (6): e0147722. [PMID:37219453] |
2. Dawson R, Diacon AH, Takuva S, Liu Y, Zheng B, Karwe V, Hafkin J. (2024)
Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy. Trials, 25 (1): 70. [PMID:38243296] |
3. Hariguchi N, Chen X, Hayashi Y, Kawano Y, Fujiwara M, Matsuba M, Shimizu H, Ohba Y, Nakamura I, Kitamoto R et al.. (2020)
OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor. Antimicrob Agents Chemother, 64 (6). [PMID:32229496] |